A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea

1. Adults and paediatric patients aged 3 months and older, who have been administered at least one dose of Zavicefta for the treatment of one of the indications as follows:
   • Complicated intra-abdominal infection (cIAI)
   • Complicated urinary tract infection (cUTI), including pyelonephritis
   • Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)
   • Other aerobic Gram-negative organism infection with limited treatment options
2. Adults 19 years of age or older, who have been administered at least one dose of Zavicefta for the treatment of the indication as follows:

•Bacteremia associated with or suspected to be associated with cIAI, cUTI or HAP including VAP.

3. Patients are treated with Zavicefta for the first time
4. Patients have signed the data privacy statement.